Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD

• Status: Completed
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesized that the empirical use of fluoroquinolones together with beta-lactam antibiotics will change their therapeutic success in patients with acute exacerbations of COPD compared to that in patients in whom a single beta-lactam treatment was used. The main goal of this study was to compare the clinical and bacterial success from the use of a combination of beta-lactam and fluoroquinolone antibiotics with that of a single beta-lactam treatment, in adult patients with COPD exacerbations.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Haiphong University of Medicine and Pharmacy
• Treatments: beta-Lactams; Cefixime; Cefotaxime; Ceftazidime; Ceftriaxone; Ciprofloxacin; Clavulanic Acid; Ertapenem; Fluoroquinolones; Imipenem; Lactams; Levofloxacin; Meropenem; Moxifloxacin; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Ticarcillin

Criteria

Inclusion Criteria:

• diagnosed with COPD stages I-IV with acute exacerbations

• incompetence to use medication by mouth

• fever

• antibiotic usage for longer than 1 day

• treatment with systemic administration of corticosteroids

• signs of pneumonia on radiographs

• history of mechanical ventilation during acute exacerbations of COPD in the past

Exclusion Criteria:

• recently detected or unresolved pulmonary malignancy

• other infectious diseases requiring antibiotic treatment

• kidney failure